Phase I study of an Epstein-Barr Virus (EBV) in healthy volunteers. The vaccine works by targeting EBV glycoprotein gp350, which is found on the surface of the virus and virus-infected cells. EBV gp350 is also the primary target for neutralizing antibodies found in the blood of people naturally infected with EBV. The study is recruiting 40 healthy adults age 18-29.
https://nihrecord.nih.gov/2022/05/27/ni ... rr-vaccine
It’s been 2.5 years since the study was posted to ClinicalTrials.gov and it’s still in the recruiting status.
https://www.clinicaltrials.gov/ct2/show ... w=2&rank=1
Epstein-Barr Virus Vaccine, Phase I
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1737 Views
-
Last post by Tif
-
- 1 Replies
- 384 Views
-
Last post by Leonard
-
- 1 Replies
- 83 Views
-
Last post by vesta
-
- 2 Replies
- 1029 Views
-
Last post by DIM
-
- 0 Replies
- 1377 Views
-
Last post by Tif
-
- 0 Replies
- 1972 Views
-
Last post by Tif
-
- 0 Replies
- 1491 Views
-
Last post by Tif
-
- 1 Replies
- 1129 Views
-
Last post by 1eye
-
- 4 Replies
- 2477 Views
-
Last post by NHE